LPA
ENSG00000198670
Chromosome
6
- Chemical probe available
- No
- Other names
- Lp(a)
- Target name
- LPA
- Gene name
- Lipoprotein(a)
- Gene symbol
- LPA
- Previous gene symbols
- LP
- Protein name
- Apolipoprotein(a) (Apo(a)) (Lp(a)) (EC 3.4.21.-)
- Gene biotype
- Protein coding
- Gene family
- Kringle domain containing
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 14.98
- Tissue specificity (Gini)
- 0.936
- Tissue specificity (tau)
- 0.996
- KEGG gene identifiers
- hsa:4018
- Reactome pathways
- R-HSA-8964041
- Protein interaction confidence
- 0.826413
- Protein interaction partners
- 46
- End position
- 160664275
- Start position
- 160531482
- Chromosome
- 6
- Strand
- Reverse
- Tissue specificity (tau)
- 0.996461
- Expression inequality (Gini)
- 0.935596
Expression in transcripts per million
- Liver
- 14.98
- Testis
- 0.67
- Prostate
- 0.29
- Brain - Hypothalamus
- 0.23
- Brain - Cortex
- 0.15
Expression in transcripts per million
- Liver14.98
- Testis0.67
- Prostate0.29
- Brain - Hypothalamus0.23
- Brain - Cortex0.15
- Brain - Anterior cingulate cortex (BA24)0.15
- Fallopian Tube0.14
- Pancreas0.13
- Brain - Frontal Cortex (BA9)0.12
- Ovary0.1
- Bladder0.1
- Kidney - Cortex0.09
- Esophagus - Mucosa0.05
- Brain - Amygdala0.05
- Pituitary0.05
- Uterus0.05
- Cervix - Endocervix0.04
- Adrenal Gland0.04
- Vagina0.03
- Thyroid0.03
- Kidney - Medulla0.03
- Brain - Hippocampus0.03
- Brain - Nucleus accumbens (basal ganglia)0.03
- Lung0.02
- Small Intestine - Terminal Ileum0.02
And 29 more, listed on the interactive page.
Biological processes
- GO:0008015
- GO:0005576
- GO:0034358
- GO:0001968
- GO:0004252
- GO:0004866
- GO:0005515
- GO:0034185
Related records
Trials (11)
- A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)
- A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
- A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Olpasiran Expanded Access Program
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
Drugs (2)
- Olpasiran LPA mRNA rnai inhibitor
- Pelacarsen LPA mRNA antisense inhibitor